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Abstract
Deliberate and natural outbreaks of infectious disease underscore the necessity of effective vaccines and antimicrobial/
antiviral therapeutics. The prevalence of antibiotic resistant strains and the ease by which antibiotic resistant bacteria can be
intentionally engineered further highlights the need for continued development of novel antibiotics against new bacterial
targets. Isoprenes are a class of molecules fundamentally involved in a variety of crucial biological functions. Mammalian
cells utilize the mevalonic acid pathway for isoprene biosynthesis, whereas many bacteria utilize the methylerythritol
phosphate (MEP) pathway, making the latter an attractive target for antibiotic development. In this report we describe the
cloning and characterization of Francisella tularensis MEP synthase, a MEP pathway enzyme and potential target for
antibiotic development. In vitro growth-inhibition assays using fosmidomycin, an inhibitor of MEP synthase, illustrates the
effectiveness of MEP pathway inhibition with F. tularensis. To facilitate drug development, F. tularensis MEP synthase was
cloned, expressed, purified, and characterized. Enzyme assays produced apparent kinetic constants (KM
DXP=104 mM,
KM
NADPH=13mM, kcat
DXP=2s
21, kcat
NADPH=1.3 s
21), an IC50 for fosmidomycin of 247 nM, and a Ki for fosmidomycin of
99 nM. The enzyme exhibits a preference for Mg
+2 as a divalent cation. Titanium dioxide chromatography-tandem mass
spectrometry identified Ser177 as a site of phosphorylation. S177D and S177E site-directed mutants are inactive, suggesting
a mechanism for post-translational control of metabolic flux through the F. tularensis MEP pathway. Overall, our study
suggests that MEP synthase is an excellent target for the development of novel antibiotics against F. tularensis.
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Introduction
The US Centers for Disease Control and Prevention (CDC)
classify biothreat agents based upon their ease of dissemination,
associated morbidity/mortality rates, projected social impact, and
emergency response procedures. Category A agents (i.e. those of
highest concern) include Bacillus anthracis (the causative agent of
anthrax), Yersinia pestis (plague), and Francisella tularensis (tulare-
mia), while category B agents (exhibiting lower morbidity/
mortality rates) include Brucella species (brucellosis), Burkholderia
mallei (glanders), and Burkholderia pseudomallei (melioidosis). The
1984 Rajneeshee Salmonella attack, 2001 anthrax letter attacks,
2003 SARS outbreak, and 2009 H1N1 swine flu pandemic
illustrate our vulnerability to both deliberate and natural
outbreaks of infectious disease and underscore the necessity of
effective vaccines and antimicrobial/antiviral therapeutics. The
prevalence of antibiotic resistant strains and the ease by which
antibiotic resistance can be engineered into bacteria further
highlights the need for continued development ofnovel antibiotics
against new bacterial targets.
Isoprenoids are a class of molecules fundamentally involved in
a variety of crucial biological functions including electron
transport (quinones), cell wall biosynthesis (dolichols), signal
transduction (prenylated proteins), and the regulation of
membrane fluidity (hopanoids and cholesterol). Despite their
structural and functional diversity, all isoprenoids are derived
from two building blocks, isopentenyl diphosphate (IPP) and
dimethylallyl diphosphate (DMAPP), which originate from either
the mevalonic acid (MVA) or methylerythritol phosphate (MEP)
pathway (Fig. 1). Because mammalian cells exclusively utilize the
MVA pathway, enzymes within the MEP pathway make an
attractive target for the development of novel antimicrobials
(reviewed in [1–3]).
Genome sequences reveal that Francisella, Brucella, Bacillus,
Burkholderia, and Yersinia each harbor MEP pathway genes, but
little else is known about isoprene biosynthesis in these biothreat
agents. In this report we describe the characterization of F.
tularensis MEP synthase, a MEP pathway enzyme and potential
target for drug development. The F. tularensis MEP synthase gene
was cloned, expressed in Escherichia coli, and the recombinant
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translational modification (phosphorylation) was revealed by
protein mass spectrometry and correlated with the loss of enzyme
activity, suggesting a possible regulatory mechanism. The stability
of F. tularensis MEP synthase in high-throughput type assays
amenable to drug development was also evaluated. Overall, our
results suggest that MEP synthase is an excellent target for the
development of novel antibiotics against F. tularensis.
Materials and Methods
Bacterial strains and growth conditions
The following reagents were obtained through the NIH
Biodefense and Emerging Infections Research Resources Repos-
itory, NIAID, NIH: Francisella tularensis subsp. holarctica Strain LVS
(FSC 155) and Francisella tularensis subsp. novicida Strain Utah 112.
Each was cultured at 37uC in tryptic soy broth supplemented with
0.1% cysteine or in modified Chamberlain’s Defined Medium
(0.4 g/L L-Arginine, 0.4 g/L L-Aspartic acid, 0.2 g/L L-Cysteine,
0.2 g/L L-Histidine, 0.4 g/L L-Isoleucine, 0.4 g/L L-Leucine,
0.4 g/L L-Lysine, 0.4 g/L L-Methionine, 2.0 g/L L-Proline,
0.4 g/L L-Serine, 2.0 g/L L-Threonine, 0.4 g/L L-Tyrosine,
0.4 g/L L-Valine, 0.04 g/L Spermine phosphate, 0.004 g/L
Thiamine HCl, 0.002 g/L L-Calcium pantothenate, 4.0 g/L
Glucose, 10.0 g/L NaCl, 0.135 g/L MgSO4 7H2O, 1.0 g/L
KH2PO4, 1.0 g/L K2HPO4, 1.92 g/L sodium citrate, 0.02 g/L
FeSO4 7H2O, pH 6.2). Escherichia coli BL21 CodonPlus (DE3)-RIL
cells (Stratagene, La Jolla, CA) were used for recombinant protein
expression whereas E. coli TOP10 (Invitrogen, Carlsbad, CA) or
XL1Blue (Stratagene) cells were used for general cloning
procedures. E. coli was grown at 37uC in Luria-Bertani (LB)
media with constant shaking (250 rpm). Protein expression was
performed in LB media containing ampicillin (100 mg/ml) and
chloramphenicol (50 mg/ml). Solid media were prepared by
addition of 1.5% (wt/vol) agar.
Fosmidomycin IC50 determination
The half-maximal inhibitory concentration (IC50) was deter-
mined via a dose-response plot of fractional growth (OD595 in the
presence of inhibitor/OD595 in the absence of the inhibitor) as a
function of fosmidomycin concentration. An overnight culture of
F. tularensis subsp. novicida was harvested by centrifugation, diluted
to an OD595=1.0, then used to inoculate modified Chamberlain’s
Defined Medium (using a 96-well plate; 17 mL of inoculum was
Figure 1. The two isoprene biosynthetic pathways. A) The MVA Pathway. The first two enzymes of the MVA pathway condense 3 molecules of
acetyl-CoA (1) to form 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) (3), which is subsequently reduced to MVA (4) by HMG-CoA reductase [20,21].
MVA is phosphorylated twice then decarboxylated to yield IPP (7) [22–24], which is converted to DMAPP (8) by an isomerase [25]. B) The MEP
Pathway. Condensation of pyruvate (9) with glyceraldehyde 3-phosphate (10) yields 1-deoxy-D-xylulose 5-phosphate (DXP; (11)) [26], an intermediate
with a role in E. coli vitamin B1 and B6 biosynthesis [27–30] and isoprene biosynthesis. 1-Deoxy-D-xylulose 5-phosphate reductoisomerase (also called
MEP synthase or IspC) catalyzes the reduction and rearrangement of 11 to yield MEP (12) [5], the first committed step in the E. coli MEP pathway. The
next enzyme, CDP-ME synthase, converts MEP into 4-(cytidine 59-diphospho)-2-C-methyl-D-erythritol (CDP-ME; (13)). CDP-ME kinase then
phosphorylates CDP-ME, which is subsequently cyclized (coupled with the loss of CMP) by cMEPP synthase to yield 2-C-methyl-D-erythritol 2,4-
cyclodiphosphate (15) [31–35]. A reductive ring opening of 15 produces 1-hydroxy-2-methyl-2-butenyl diphosphate (HMBPP; (16)) [12,36–39], which
is subsequently reduced to both IPP and DMAP in a ,5:1 ratio [2,40–45]. C) The reaction catalyzed by MEP synthase. Isomerization via cleavage of the
bond between C3 and C4 and formation of a new bond between C2 and C4 produces the intermediate 2-C-methyl-D-erythrose 4-phosphate (18)
[46,47], which is subsequently reduced to yield MEP (12).
doi:10.1371/journal.pone.0008288.g001
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fosmidomycin). All conditions were evaluated in duplicate.
Bacterial growth (OD595 at 37uC) was determined using a
Beckman Coulter DTX800 plate reader. A nonlinear regression
analysis was carried out on the data obtained using GraphPad
PRISM version 4.00 for Windows (GraphPad Software Inc., San
Diego, CA) and the equation F =1/(1+[I]/IC50) where F =
fractional growth and [I] = inhibitor concentration.
Genomic and Plasmid DNA isolation
F. tularensis subsp. holarctica genomic DNA was isolated using a
Wizard Genomic DNA Purification Kit (Promega, Madison, WI),
per the manufacturer’s instructions. Plasmid DNA was isolated
from E. coli using a GenElute Plasmid miniprep kit (Sigma-
Aldrich, St. Louis, MO).
Construction of the F. tularensis MEP synthase expression
plasmid
The MEP synthase coding region (ispC) was identified in the F.
tularensis subsp. holarctica LVS genome (accession number
NC_007880) via a BLAST search using the E. coli K12
homologous sequence as the query. Polymerase chain reaction
(PCR) primer pairs, designed to flank ispC (FtIspC-f; 59-
CACCATGTTTAAAAAAACTAAGATTAC -39 and FtIspC-r;
59- CCCCAAAACAGAATCCACATATTC -39), were purchased
from Sigma-Genosys (The Woodlands, TX) and used to amplify
the gene from F. tularensis subsp. holarctica LVS genomic DNA.
FtIspC-f contains four additional 59 residues (CACC) to facilitate
the unidirectional insertion of the PCR product into plasmid
pET101/D-TOPO (Invitrogen). FtIspC-r is designed to eliminate
the stop codon in the PCR product to permit the expression of a
C-terminal His-tagged MEP synthase protein. PCR was per-
formed with Platinum Pfx polymerase (Invitrogen) and the
following parameters: 2 minutes at 94uC followed by 22 cycles
of 15 sec at 94uC, 30 sec at 54uC, 1.5 min at 68uC, and a final
elongation of 10 min at 68uC. The PCR product was purified
using the Qiaquick PCR Purification Kit (Qiagen, Valencia, CA)
and cloned into pET101/D-TOPO to create pFtIspC. Restriction
mapping and DNA sequencing were used to confirm the fidelity of
the PCR and the correct construction of the plasmid. pFtIspC was
transformed into chemically competent E. coli BL21 CodonPlus
(DE3)-RIL cells to express the protein.
Expression and purification of F. tularensis MEP synthase
A one liter shake flask was used for protein expression (37uC,
250 rpm). The flask was inoculated with a 10 mL overnight
culture of E. coli BL21 CodonPlus (DE3)-RIL containing pFtIspC
and upon reaching an OD600 of 1.1, protein expression was
induced by the addition of 0.5 mM isopropyl b-D-thiogalactopyr-
anoside (IPTG). After incubation for an additional 18 hours, cells
were harvested by centrifugation and stored at 280uC. To purify
the His-tagged protein, the cell pellet was thawed then cells were
lysed using Lysis Buffer A (100 mM Tris pH 8, .032% lysozyme;
3 mL per mg cell pellet), followed by Lysis Buffer B (0.1 M CaCl2,
0.1 M MgCl2, 0.1 M NaCl, .020% DNase; 0.3 mL per mg cell
pellet). Clarified cell lysate was obtained by centrifugation (48,000
x g, 20 min) then passed through a TALON immobilized metal
affinity chromatography column (Clontech Laboratories, Moun-
tain View, CA). The column was washed with 15 column volumes
of 1X equilibration buffer (50 mM HEPES pH 7.5, 300 mM
NaCl), 10 column volumes of 1X wash buffer (50 mM HEPES
pH 7.5, 300 mM NaCl, 10 mM imidazole), 10 column volumes of
2X wash buffer (100 mM HEPES pH 7.5, 600 mM NaCl,
20 mM imidazole), and the His-tagged protein was then eluted
with 5 column volumes of 1X elution buffer (150 mM imidazole
pH 7.0, 300 mM NaCl). Buffer was exchanged by addition of
0.1 M Tris pH 7.5, 1 mM NaCl, 5 mM DTT while concentrating
the protein by ultrafiltration. Protein concentration was deter-
mined using the Advanced Protein Assay Reagent (Cytoskeleton,
Denver, CO) with c-globulins (Sigma-Aldrich) as the standard.
The protein was visualized via Coomassie stained SDS-PAGE and
a Western blot with an anti-His antibody (Qiagen). The yield of
purified MEP synthase averaged 5–10 mg per 1 L LB shake flask.
Size-Exclusion Chromatography
The molecular mass of MEP synthase and the mutant
derivatives were estimated by loading 1 mg of protein onto a
Sephacryl 200HR (Sigma Aldrich, St. Louis, MO) size-exclusion
chromatography column equilibrated with 0.1 M Tris pH 7.5,
1 mM NaCl, 5 mM DTT (flow rate of 2 mL/min) and calibrated
with a gel filtration standard kit purchased from Bio-Rad
(Hercules, CA). Blue dextran was used to determine the void
volume of the column.
Mutagenesis
The Ser177 to Asp177 mutant of MEP synthase was created via
PCR based site directed mutagenesis using primers FT-IspC-
SD177-FP (59 TTA ACA GCA gaT GGA GGT CCT TTT AG
39; lowercase residues indicate site of mutation) and FT-IspC-
SD177-RP (59 AGG ACC TCC Atc TGC TGT TAA AAT TAT
C3 9), whereas the Ser177 to Glu177 mutant was created using
primer pairs FT-IspC-SE177-FP (59 TTA ACA GCA gaa GGA
GGT CCT TTT AGA G 39) and FT-IspC-SE177-RP (59 AGG
ACC TCC ttc TGC TGT TAA AAT TAT C 39). Each primer
pair is oriented outward from a central overlapping region. In the
first step of the mutagenesis, four unidirectional PCRs were
performed with each of the four individual PCR primers (FT-
IspC-SD177-FP, FT-IspC-SD177-RP, FT-IspC-SE177-FP, or
FT-IspC-SE177-RP) using the following parameters: 5 minutes
at 95uC followed by 30 cycles of 30 sec at 95uC, 30 sec at 60uC,
40 sec at 72uC, and a final elongation of 7 min at 72uC. In the
second step, 5 mL of each PCR product was appropriately
combined with the product obtained from the companion primer
(i.e. the product using FT-IspC-SD177-FP was combined with the
FT-IspC-SD177-RP product, whereas the products obtained from
the PCRs with FT-IspC-SE177-FP and FT-IspC-SE177-RP were
combined) and each mixture served as template for a subsequent
PCR using T7 forward and reverse primers. PCR conditions were
as follows: 5 minutes at 95uC followed by 5 cycles of 30 sec at
95uC, 30 sec at 60uC, 40 sec at 72uC, then 25 cycles of 30 sec at
95uC, 30 sec at 52uC, 40 sec at 72uC and a final elongation of
10 min at 72uC. In the third step, the PCR products from step 2
were amplified using primers FtIspC-f and FtIspC-r (described
above), and the resulting products were cloned into pET101/D-
TOPO, transformed into XL1Blue cells, and sequence confirmed
by restriction digestion and nucleotide sequencing. Each expres-
sion vector was introduced into chemically competent E. coli BL21
CodonPlus (DE3)-RIL cells to express the C-terminal His-tagged
protein. The S177D and S177E mutants were purified as
described for the wildtype His-tagged MEP synthase.
Fluorescence spectroscopy
Fluorescence spectra of MEP synthase and the mutant
derivatives were measured using a Fluoromax-3 fluorometer
(Horiba Jobin Yvon) at an excitation wavelength of 290 nm using
cuvettes with an optical path length of 1 cm. The emission spectra
of protein samples with a concentration of 5 mM in 0.1 M Tris
F. tularensis MEP Synthase
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400 nm (excitation and emission slit width =5 nm). The
temperature was maintained at 30uC. All fluorescence spectra
were corrected for background with pure buffer.
Enzyme Assays
MEP synthase activity was evaluated at 22uC by spectropho-
tometrically monitoring the enzyme catalyzed oxidation of
NADPH using an assay derived from that described by Takahashi
et al [4]. All assays were performed in triplicate. To determine the
apparent KM for 1-deoxy-D-xylulose 5-phosphate (DXP), assay
mixtures (200 mL) contained 100 mM Tris pH 7.8, 25 mM
MgCl2, 0.15 mM NADPH, 7 mM MEP synthase, and a variable
concentration of DXP (Echelon Biosciences, Salt Lake City, UT).
To determine cation specificity, assays were performed with
25 mM MgCl2, CaCl2, CoCl2, CuCl2, MnCl2, ZnCl2, or NiCl2.
To determine the apparent KM for NADPH, assays were
performed with fixed DXP concentration (0.4 mM) and variable
NADPH concentration. Nonlinear regression fitting to the
Michaelis-Menten equation was used to determine the kinetic
constants. Half-maximal inhibition (IC50) by fosmidomycin was
determined using a plot of enzyme fractional activity as a function
of inhibitor concentration. A plot of KM
app as a function of inhibitor
concentration was used to determine the Ki for fosmidomycin
(negative value of the x intercept). Because fosmidomycin is a slow,
tight binding inhibitor [5], the enzyme was preincubated with
fosmidomycin for 10 minutes prior to addition of substrate. High-
throughput assays were performed using 96-well plates with assay
volumes adjusted to 100 mL. The Z-factor was calculated as
described by Zhang et al [6] with fosmidomycin as the inhibitor
control.
Mass spectrometry method for phosphopeptide
identification
To obtain MEP synthase for phosphopeptide analysis, protein
expression and purification was essentially as described above,
with the exception of using 0.01 mM IPTG for induction. Purified
MEP synthase was reduced with 10 mM dithiothreitol (DTT),
alkylated by iodoacetamide (50 mM), and then digested by trypsin
(Promega) in buffer containing ammonium bicarbonate (50 mM,
pH 9) and urea (2 M). The digestion mixture was then desalted by
a SepPak column (Waters, Milford, MA). Phosphopeptides were
enriched from the tryptic peptides by a TiO2 column as described
by Thingholm et al [7] with modification. In brief, 30 cm fused
silica capillary tubing (360 mm OD, 200 mm ID, Polymicro
Technologies, Phoenix, AZ) was attached to the frit end of Inline
MicroFilter Assembly (Upchurch Scientific), and TiO2 loose
media (GL Sciences, Inc) was slurry-packed into the tubing using
a Pressure Cell (Brechbu ¨hler Inc.) to form a 200 mm62 cm TiO2
column. The SepPak-cleaned sample was mixed with equal
volume of Loading Buffer (200 mg/mL 2,5-dihydroxybenzoic acid
(DHB), 5% trifluoroacetic acid (TFA), 80% acetonitrile), and
loaded into TiO2 column by Pressure Cell with flow rate of 3 mL
per minute. The column was washed with 200 mL Wash Buffer 1
(40 mg/ml DHB, 2% TFA, 80% acetonitrile) and 26200 mL
Wash Buffer 2 (2% TFA, 50% acetonitrile) to remove non-
phosphopeptides. Phosphopeptides were then eluted off the
column by Elution Buffer (5% ammonia solution). Ammonia in
the eluate was evaporated by SpeedVac (,3 min), acidified by
adding glacial acetic acid to a final concentration of 2%, and
desalted using a ZipTip (Millipore). The purified phosphopeptides
were analyzed by reversed-phase liquid chromatography nanos-
pray tandem mass spectrometry (LC-MS/MS) using an LTQ-
Orbitrap mass spectrometer (ThermoFisher) using previously
described methods [8]. Tandem mass spectra were searched using
the program SEQUEST (Bioworks software, Thermo) with full
tryptic cleavage constraints, static cysteine alkylation by iodoace-
tamide, and variable phosphorylation of Ser/Thr/Tyr. Phospho-
peptide identification was determined using database match
scoring criteria filters followed by manual evaluation of the raw
data, as described [8].
Molecular Modeling
F. tularensis subsp. holarctica LVS MEP synthase (protein
accession number CAJ78974) was homology-modeled using
SWISS-MODEL [9] (http://swissmodel.expasy.org/) in automat-
ed modeling mode. The template used for modeling was identified
via the template identification tool (with default parameters),
which performs a primary sequence comparison of the query
sequence with those in a structural database. The resolved
structure that exhibited the greatest sequence homology with F.
tularensis MEP synthase was chosen as the template for modeling
(E. coli MEP synthase; PDB ID# 1T1R, BLAST e val-
ue=3610
294, 48% identity and 66% homology with the F.
tularensis sequence). The quality of the F. tularensis MEP synthase
model was evaluated using ProQRes[10], which uses atom-atom
contacts, residue-residue contacts, solvent accessibility, and
secondary structure information to assign an accuracy score from
0 (unreliable) to 1 (reliable). Swiss-PdbViewer 4.0 (http://spdbv.
vital-it.ch/) was used to visualize and annotate the model.
Results and Discussion
The F. tularensis MEP pathway as an antimicrobial target
Since MEP pathway orthologs are not found in the human
genome, the pathway makes an attractive target for the
development of novel antibiotics. To assess if MEP pathway
inhibition would restrict the in vitro proliferation of F. tularensis
subsp. novicida, we monitored bacterial growth in media supple-
mented with fosmidomycin[11], a strong and specific inhibitor of
MEP synthase (E. coli genetically engineered to use mevalonate for
IPP biosynthesis (Fig. 1) is unaffected by fosmidomycin when the
culture medium is supplemented with mevalonate, but growth is
inhibited by fosmidomycin when mevalonate is excluded[12],
illustrating the specificity of fosmidomycin for the MEP pathway.
Figure 2. Dose-response plot of F. tularensis subsp. novicida
growth as a function of fosmidomycin concentration. Fractional
growth was calculated as the ratio of cell density (OD595) in the
presence of inhibitor to cell density in the absence of inhibitor.
Nonlinear regression fitting indicates half maximal activity at 12 mM.
The goodness-of-fit (R
2) value is indicated. Growth curves are presented
in supportive Fig. S1.
doi:10.1371/journal.pone.0008288.g002
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and a resolved crystal structure of E. coli MEP synthase bound to
the inhibitor[13] further illustrate this specificity). As illustrated in
the dose-response plot shown in Fig. 2, fosmidomycin inhibits F.
tularensis growth, with half-maximal inhibition at 12 mM (2.2 mg/
mL). A transposon mutant library of F. tularensis [14] further
confirms the essentiality of the pathway, as MEP pathway
knockouts are lethal, further validating the pathway as an
attractive target in F. tularensis. To facilitate drug development,
we next set out to clone and evaluate MEP synthase.
Cloning, expression, and purification of F. tularensis MEP
synthase
The F. tularensis subsp. holarctica LVS ispC gene, identified via a
BLAST search of the genome using the E. coli K12 homologous
sequence, is 1158 bp in length and encodes a polypeptide of 385
amino acids with a calculated molecular mass of 42.7 kDa. The
subsp. holarctica MEP synthase amino acid sequence shares 99.7,
99.0, and 99.7% identity with the MEP synthase sequence from
subsp. tularensis, subsp. novicida, and subsp. mediasiatica, respectively.
PCR primer pairs, designed to flank the subsp. holarctica ispC, were
used to amplify the gene. The PCR product was cloned into an
expression plasmid engineered to express a C-terminal His-tagged
protein in E. coli. Purified protein was visualized by SDS-PAGE
and Western blot hybridization using an anti-His antibody (Fig. 3).
Figure 3. Purification of recombinant F. tularensis MEP syn-
thase. A) Coomassie stained SDS-PAGE showing a molecular weight
marker (MW) and purified His-tagged MEP synthase. His-tagged MEP
synthase has a predicted molecular weight of 46.4 kDa. B) Western blot
hybridization analysis of purified MEP synthase using an anti-His
antibody results in an intense band of the expected size. The
appearance of a weak, smaller molecular weight band suggests that
some degradation may have occurred.
doi:10.1371/journal.pone.0008288.g003 Figure 4. The substrate dependent activity of F. tularensis MEP
synthase. Michaelis-Menten plots of reaction velocity as a function of
A) DXP concentration and B) NADPH concentration were used to derive
the kinetic parameters listed in Table 1. The solid line represents the
nonlinear least-squares best fit of the data to the Michaelis-Menten
equation. The R
2 value for each plot is indicated.
doi:10.1371/journal.pone.0008288.g004
Table 1. MEP synthase Apparent Kinetic Parameters.
MEP synthase
KM
DXP
(mM)
KM
NADPH
(mM)
kcat
DXP
(s
21)
kcat
NADPH
(s
21)
kcat
DXP/KM
DXP
(M
21min
21)
IC50
fosmidomycin
(nM)
Ki
fosmidomycin
(nM) Refer.
F. tularensis
a 103.7 +/2 12.1 13.3 +/2 1.5 2.0+/2 0.09 1.3+/2 0.04 1.2610
6+/2 9610
4 247 98.9 +/2 4.5 This study
E. coli 81–175 0.5–18 33 - 2.4610
7 35 21–215 [5,33,49,50]
M. tuberculosis 47 29.7 1.2 - 1.5610
6 310 - [51]
Synechocystis sp. PCC6803 170 3.5 17 - 6610
6 - 4 [16,52]
aThe values were calculated from data obtained in triplicate.
doi:10.1371/journal.pone.0008288.t001
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vealed that F. tularensis MEP synthase exists in solution as a dimer
of ,94 kDa (Fig. S2), similar to MEP synthase from Mycobacterium
tuberculosis[15] and Synechocystis sp. PCC6803[16].
Kinetic characterization of F. tularensis MEP synthase
The kinetic activity of purified MEP synthase was spectropho-
tometrically evaluated by monitoring the substrate dependent
enzyme catalyzed oxidation of NADPH (Fig. 1C). Nonlinear
regression fitting of enzyme velocity versus substrate concentration
was used to determine the apparent kinetic constants (Fig. 4 and
Table 1). The KM
app for 1-deoxy-D-xylulose 5-phosphate (DXP)
was obtained using assays performed with a saturating concentra-
tion of NADPH (150 mM), whereas the KM
app for NADPH was
determined using assays with saturating levels of DXP (400 mM).
The KM
app, DXP and KM
app, NADPH for recombinant F. tularensis MEP
synthase are consistent with values reported for the enzyme from
E. coli, M. tuberculosis, and Synechocystis sp. PCC6803 (Table 1). The
apparent specificity constant of F. tularensis MEP synthase is also
comparable to the Mycobacterium and Synechocystis enzymes,
although it is 20 fold less than that reported for the E. coli enzyme
(due to the difference in kcat
DXP). Assays performed with various
divalent cations revealed that recombinant F. tularensis MEP
synthase prefers MgCl2, although 60% of the enzyme activity is
retained with MnCl2 (Fig. 5).
Having established assay conditions for F. tularensis MEP
synthase, we set out to evaluate the protein sensitivity to
fosmidomycin. Half maximal activity (IC50) was observed at
247 nM, similar to that reported for the Mycobacterium homolog
(Table 1). The Ki for fosmidomycin (99 nM), obtained from a plot
of KM
app, DXP as a function of inhibitor concentration (Fig. 6), is
greater than that reported for E. coli and Synechocystis sp.
PCC6803 (Table 1). This may reflect structural differences in
the MEP synthase homologs, although this remains to be
determined.
F. tularensis MEP synthase in a high-throughput assay
One method of identifying lead molecules in the drug
development process involves the screening of large molecular
libraries for inhibitors of an assay. A crucial issue for reliable high-
throughput screening is the quality and robustness of the assay,
often described in terms of the Z-factor [6]. An assay with a Z-
factor score between 0.5 and 1.0 is considered excellent for high-
throughput screening. To determine the Z-factor for the assay
using F. tularensis MEP synthase, we adjusted the assay volume to
accommodate a 96-well plate, fixed the substrate concentration at
the KM (104 mM), used a saturating concentration of NADPH
(150 mM), and evaluated three separate lots of purified MEP
synthase in a series of assays performed over three consecutive
days. Fosmidomycin was used as a positive control for inhibition.
The Z-factor with F. tularensis MEP synthase was found to be 0.8,
indicative of an assay (and enzyme) well suited for use in a high-
throughput screen.
Figure 5. The divalent cation specificity of F. tularensis MEP
synthase. Enzyme assays were performed with several different
divalent cations at a fixed DXP (150 mM) and NADPH (100 mM)
concentration. Relative enzyme activity reveals the preference of the
enzyme for Mg
+2.
doi:10.1371/journal.pone.0008288.g005
Figure 6. Graphical determination of the inhibition constant. Because fosmidomycin is a slow, tight binding inhibitor [5], the enzyme was
preincubated with fosmidomycin for 10 minutes prior to addition of substrate. The absolute value of the x intercept of the line produced from linear
regression fitting the plot of KM
app,DXP as a function of fosmidomycin concentration defined the Ki as 98.9 +/2 4.5 nM. The R
2 value is indicated.
doi:10.1371/journal.pone.0008288.g006
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The first committed and principle regulatory step in the MVA
pathway is catalyzed by HMG-CoA reductase (reviewed in [17]).
Multifaceted control mechanisms regulate HMG-CoA reductase
activity, including the modulation of enzyme concentration, the
modulation of membrane composition/fluidity, and the regulation
of enzyme activity via reversible phosphorylation (specifically,
enzyme inhibition by phosphorylation of a serine residue in the
catalytic domain [18]). In comparison to the MVA pathway, much
less is known about the regulatory mechanisms that control
metabolic flux through the MEP pathway. Engineered alterations
of MEP pathway gene expression suggest that several MEP
pathway enzymes may share control over metabolic flux (reviewed
in [19]). The role of posttranslational modification, such as
reversible phosphorylation, remains unknown. Thus, we sought to
evaluate if a phosphorylation site on F. tularensis MEP synthase
could be identified.
Recombinant F. tularensis MEP synthase was purified from E. coli
(induced with 10 mM IPTG), subjected to trypsinization, and
phosphopeptides were isolated and identified via titanium dioxide
chromatography-tandem mass spectrometry. Phosphoserine 177
(equivalent to Ser186 in the E. coli enzyme) was identified (Fig. 7). E.
coli Ser186 is located in the substrate binding site, directly interacts
with the substrate, and participates in additional interactions that
contribute towards protein conformational changes that occur upon
substrate binding [13]. Serine 177 presumably has a similar role in
the F. tularensis homolog. Phosphorylation of Ser177 is likely to
disrupt these interactions, influencing substrate binding and protein
conformation, ultimately affecting enzyme activity. To test this
assumption, two mutants of F. tularensis MEP synthase were created,
S177D and S177E, wherein Ser177 was changed to an aspartate or
glutamate, respectively, which serve to mimic a phosphoserine.
Each mutant was expressed in E. coli and purified to near
homogeneity via a C-terminal His-tag. Relative to wildtype MEP
Figure 7. Predicted tertiary structure of F. tularensis MEP synthase, homology-modeled using SWISS-MODEL. A crystal structure of F.
tularensis MEP synthase has not been reported. To permit the visualization of phosphoserine177 within the context of the tertiary structure, the F.
tularensis MEP synthase was modeled based upon the resolved structure of the E. coli homolog[48] (48% identity, 66% homology). A cartoon
representation of the model is shown, with alpha helices colored red, beta sheets colored yellow, and coiled regions colored gray. The beta sheets
comprise the dimer interface in the E. coli structure. The quality of the model was evaluated with ProQRes (Fig. S3) which provides scores ranging
from 0 (unreliable) to 1 (reliable). Regions of the model scoring ,0.5 are colored light blue. Primary sequence alignment and the structure of E. coli
MEP synthase were used to identify residues comprising the substrate binding site (colored dark blue with backbone and sidechain residues shown).
Serine177 (colored green with backbone and sidechain residues shown) is equivalent to E. coli Ser186, which contributes to the substrate binding site
and has been shown to participate in conformational changes that occur upon substrate binding [13]. Two tryptophan residues present in the F.
tularensis MEP synthase model are colored pink.
doi:10.1371/journal.pone.0008288.g007
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S177D suggests changes in the protein globular fold are brought
about bythe introductionoftheAspresidue (Fig.8A).Theslight red
shift in fluorescence emission spectrum of S177E is also indicative of
a conformational change, although the change in S177E suggests
exposure of a tryptophan residue to a hydrophilic environment
whereas the blue shift observed with S177D is indicative of a
conformational change sequestering a tryptophan in a hydrophobic
environment. Like the wildtype enzyme, both mutants exist as
dimers in solution, as determined by size-exclusion chromatography
(Fig. S2). Enzyme assays performed using the purified mutants
reveal that each is inactive (Fig. 8B). Collectively, these results
suggest that phosphorylation of Ser177 leads to a conformational
change in F. tularensis MEP synthase which inhibits the enzyme and
may serve as a control mechanism to regulate metabolic flux
through the MEP pathway.
Conclusions
In conclusion, we have shown that F. tularensis MEP synthase is a
valid target for the development of novel therapeutics. Inhibition of
MEP synthase is sufficient to inhibit the growth of F. tularensis in vitro.
Purified MEP synthase is kinetically active and readily lends itself to
use in high-throughput screens. Furthermore, our investigation is
the first to show that metabolic flux through the F. tularensis MEP
pathway may be regulated by phosphorylation of MEP synthase,
similar to the regulatory control observed in the MVA pathway.
Supporting Information
Figure S1 Growth curves of F. tularensis subsp. novicida in
minimal media supplemented with the indicated concentration of
fosmidomycin (FoS). All conditions were evaluated in duplicate.
Found at: doi:10.1371/journal.pone.0008288.s001 (3.20 MB TIF)
Figure S2 Molecular weight determination by size-exclusion
chromatography. Protein standards (&) were used to calibrate the
column. Linear regression fitting (R
2 is indicated) generated the
standard curve, which was used to determine the molecular weight
of IspC, S177D, and S177E.
Found at: doi:10.1371/journal.pone.0008288.s002 (1.44 MB TIF)
Figure S3 ProQRes evaluation of the F. tularensis MEP synthase
structural model generated by SWISS-MODEL. ProQRes uses
atom-atom contacts, residue-residue contacts, solvent accessibility,
and secondary structure information to score the model over a
sliding window of 9 residues[10]. Scores range from 0 (unreliable)
to 1 (reliable).
Found at: doi:10.1371/journal.pone.0008288.s003 (3.95 MB TIF)
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